Ekso Bionics Holdings, Inc. Provides Sales Guidance for the Fourth Quarter and Full Year Ended December 31, 2017
January 09, 2018 at 06:45 pm IST
Share
Ekso Bionics Holdings, Inc. provided sales guidance for the fourth quarter and full year ended December 31, 2017. For the quarter, the company expects to report revenue of over $2.5 million.
For the year, total revenue was approximately $7.4 million, compared to $7.7 million in 2016, excluding a one-time recognition of $6.5 million in 2016 of deferred revenue on previously shipped units.
Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves multiple markets and can be utilized both by able-bodied persons and persons with physical disabilities or impairments. Its products include EksoNR, which is a wearable robotic exoskeleton specifically designed to be used in a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower-limb powered exoskeleton; Ekso Indego Personal is a lightweight powered lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. The Company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate and to walk again; assist individuals with a range of upper extremity impairments and allow industrial workers to perform difficult repetitive work for extended periods. Its segments include EksoHealth and EksoWorks.
EKSO BIONICS HOLDINGS, INC. 
